What it's for (Indications)
- Domperidone is a peripheral dopamine receptor antagonist primarily indicated for the symptomatic treatment of nausea and vomiting, including that associated with chronic gastroparesis, chemotherapy, and migraine headaches.
- It is also used to alleviate symptoms of functional dyspepsia, such as epigastric fullness, early satiety, and upper abdominal discomfort.
- By enhancing gastrointestinal motility and accelerating gastric emptying, domperidone effectively manages conditions where delayed gastric emptying contributes to patient discomfort.
- Its antiemetic effects are primarily mediated through antagonism of dopamine D2 receptors in the chemoreceptor trigger zone in the brainstem, while its peripheral prokinetic activity addresses gastrointestinal stasis.
- It is generally reserved for situations where other antiemetic treatments are insufficient or contraindicated, particularly due to its potential cardiac risks and restricted usage.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended adult oral dosage of domperidone is typically 10 mg, administered up to three times daily, usually 15-30 minutes before meals and, if necessary, at bedtime. The maximum daily dose should generally not exceed 30 mg to minimize the risk of cardiac adverse effects, particularly QT prolongation and serious ventricular arrhythmias. For patients with renal impairment, a reduction in dosing frequency may be necessary; for instance, to once or twice daily, depending on the severity of renal dysfunction, as accumulation can occur. In adolescents and children, dosage should be carefully calculated based on body weight, and its use is generally reserved for very specific, severe indications under strict medical supervision due to heightened safety concerns. Treatment duration should be as short as possible and typically not exceed one week for acute nausea and vomiting. Dosage adjustments and careful monitoring are crucial for individual patient safety and efficacy, emphasizing the lowest effective dose for the shortest duration. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of domperidone include dry mouth, headache, fatigue, diarrhea, and abdominal cramping.
- However, more serious and clinically significant adverse reactions, particularly cardiovascular events, are a primary concern.
- These include dose-dependent QT prolongation, serious ventricular arrhythmias (e.
- g.
- , Torsades de Pointes), and sudden cardiac death.
- These risks are heightened in patients with pre-existing cardiac conditions, electrolyte disturbances, and concomitant use of QT-prolonging drugs or strong CYP3A4 inhibitors.
- Due to its dopamine D2 receptor antagonism, domperidone can also lead to hyperprolactinemia, manifesting as galactorrhea, gynecomastia, amenorrhea, and decreased libido.
- While domperidone generally has limited penetration of the blood-brain barrier, extrapyramidal symptoms (e.
- g.
- , dystonia, akathisia, parkinsonism) have been reported, especially in children and at higher doses.
- Hypersensitivity reactions, including rash, pruritus, and anaphylaxis, can also occur.
- Patients should be advised to report any adverse symptoms promptly to their healthcare provider.
Serious Warnings
- Black Box Warning: While domperidone is not approved for use in the United States by the FDA and therefore does not carry an official FDA black box warning, regulatory authorities in other countries (e.g., Canada, European Union) have issued stringent warnings and restrictions concerning its use due to the significant risk of serious ventricular arrhythmias and sudden cardiac death. These risks are dose-dependent and increased in patients aged over 60 years, those taking daily doses exceeding 30 mg, and individuals with pre-existing cardiac conditions (e.g., congestive heart failure, significant bradycardia, or recent myocardial infarction). The risk is further exacerbated by concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, ritonavir) or other medicinal products known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, antidepressants). Domperidone should be used at the lowest effective dose for the shortest possible duration, typically not exceeding one week for acute nausea and vomiting. It is contraindicated in patients with prolonged cardiac conduction intervals, significant electrolyte disturbances, or underlying cardiac disease. Prescribers must carefully assess the benefit-risk balance and consider safer alternatives, adhering strictly to approved indications and dosage recommendations.
- Domperidone carries significant warnings primarily related to its potential for serious cardiac adverse events, including dose-dependent QT interval prolongation, serious ventricular arrhythmias, and sudden cardiac death.
- These risks are considerably increased in patients aged over 60 years, those taking daily doses exceeding 30 mg, and individuals with pre-existing cardiac conditions such as congestive heart failure, significant bradycardia, or recent myocardial infarction.
- Concomitant use with strong CYP3A4 inhibitors (e.
- g.
- , ketoconazole, erythromycin, clarithromycin) or other drugs known to prolong the QT interval (e.
- g.
- , certain antiarrhythmics, antipsychotics, antidepressants) is contraindicated due to increased plasma levels of domperidone and enhanced cardiotoxicity.
- Patients with significant electrolyte disturbances (hypokalemia, hypomagnesemia) or underlying moderate to severe hepatic impairment should use domperidone with extreme caution, or avoid it altogether.
- It is not recommended for routine long-term use and should be used at the lowest effective dose for the shortest possible duration, typically not exceeding one week for acute indications.
- Prescribers must carefully assess the benefit-risk profile for each patient, especially considering the availability of safer alternatives for nausea and vomiting.
- Close monitoring of cardiac function may be warranted in high-risk individuals and those receiving prolonged therapy.
How it Works (Mechanism of Action)
Domperidone exerts its therapeutic effects primarily through selective antagonism of dopamine D2 and D3 receptors. Its potent antiemetic action is attributed to blockade of dopamine receptors in the chemoreceptor trigger zone (CTZ), located in the area postrema outside the blood-brain barrier. By inhibiting dopamine's emetic stimulation at the CTZ, domperidone effectively reduces nausea and vomiting. Concurrently, its prokinetic properties arise from D2 receptor antagonism in the gastrointestinal tract, specifically in the myenteric plexus. This inhibition of dopamine's inhibitory effect on cholinergic neurons leads to an enhancement of acetylcholine release. The increased cholinergic activity results in improved gastric and duodenal motility, accelerated gastric emptying, and enhanced lower esophageal sphincter tone, thereby alleviating symptoms of dyspepsia and gastroesophageal reflux. A key characteristic of domperidone is its limited ability to cross the intact blood-brain barrier, which generally results in a lower incidence of central nervous system side effects such as extrapyramidal symptoms compared to other dopamine antagonists. However, its peripheral dopamine antagonism can still induce hyperprolactinemia by disinhibiting prolactin secretion from the anterior pituitary gland.